Gamida Cell is working to provide potentially curative cell therapies to patients with cancer. The company utilizes proprietary nicotinamide (NAM) technology to enhance and expand cells for allogeneic cell therapy products and candidates targeting hematologic malignancies.

Gamida Cell

Dexcel Pharma is a privately owned pharmaceutical company developing, manufacturing, and commercializing innovative and generic products worldwide.

Dexcel Pharma

Gamida Cell Ltd. | 10,376 followers on LinkedIn. Working to turn cells into powerful therapeutics for patients with cancer.  | Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. Our proprietary nicotinamide (NAM) technology expands the number of cells while maintaining their intrinsic properties to create potentially curative cell therapy products and candidates for patients with cancer.  

Our stem cell transplant therapy was approved by the US FDA in April 2023.

CEO & Chairman, Gamida Cell

Joseph Wiley

Cell & Gene Therapy Patient Access/Services Director

Suzi Spayd, RN

Exsilio Therapeutics

Dima Yackoubov

Scientific/Medical Director | Medical Science Liaison

Dawn Marie Stull

Gamida Cell Ltd.

Mark your calendars! See what’s new with Gamida at this year’s NMDP One Forum and ASTCT Toxicities Conference.

Today, Gamida Cell announced it has commenced a restructuring process supported by Highbridge Capital Management , the company’s principal lender. This transaction is anticipated to provide the long-term financial runway needed to support ongoing commercialization of our FDA-approved cell therapy. “This restructuring transaction will enable Gamida Cell to remain a going concern and will support our ongoing efforts to make our FDA approved cell therapy product available to more transplant centers and their patients,” said Abbey Jenkins, President and CEO of Gamida Cell. Learn more in our press release: https://lnkd.in/ev5Rymmg

March marks Women’s History Month, and March 8th marks International Women’s Day. This year’s theme for International Women's Day is #InspireInclusion , which represents building a more inclusive future where women are more than just present – but a part of the conversation, valued and empowered. This month, and throughout the year, let’s celebrate the achievements of women both past and present and continue to inspire inclusivity throughout the world. #IWD2024 #WomenInStem

Michele Korfin , Chief Operating and Chief Commercial Officer at Gamida Cell, recently spoke with Newsweek ’s Investment Reports about the importance of cell therapy as an option for patients with cancer, and the efforts to broaden access to allogeneic stem cell transplant. To read the full article, visit: https://lnkd.in/gwJeeAQg Note: Gamida Cell is not responsible for and does not endorse the content found within third party websites. #celltherapy #biotech

On Employee Appreciation Day, Gamida Cell recognizes each and every one of our employees for their hard work and dedication. To all of our employees, thank you for everything you do. #EmployeeAppreciationDay #CellTherapy #Biotech

The NMDP Registry® is the world’s largest registry of stem cell transplant donors, with over 19 million potential donors and over 249,000 cord blood units (CBUs). Despite this, according to Gamida Cell market research, approximately 1,700 patients in the U.S. are unable to find a donor each year, with patients from diverse racial and ethnic backgrounds being most impacted. According to NMDP, patients who identify as Black or African American have a 29% chance of finding a match, compared with patients who identify as Asian or Pacific Islander (47%), Hispanic or Latino (48%), Native American (60%) and white (79%). According to U.S. Census data, the U.S. population is more racially and ethnically diverse than it has ever been previously. With a greater variety of HLA types, a key piece of genetic DNA needed for matching, it’s harder to find a closely matched donor. Increasing the diversity in the donor registry is key to addressing the equity gap between those who have access to a stem cell transplant and those who need one. Learn more about how a patient’s ethnic background affects donor matching here: https://lnkd.in/eBMgGEmS #healthequity #NMDP #SavingLives

Today, two posters highlighting Gamida Cell research were presented at #Tandem24 , Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy ( ASTCT ) and the Center for International Blood & Marrow Transplant Research (CIBMTR) . Mitchell E. Horwitz, MD, Stem Cell Transplant Specialist and Professor of Medicine at Duke Cancer Institute presented data from an Expanded Access Program (EAP) evaluating outcomes in patients with hematologic malignancies following allogeneic stem cell transplant with omidubicel-onlv. Brian C. Shaffer, Associate Professor of Medicine and Head of the Adult Mismatched Donor Sub-Program at Memorial Sloan Kettering Cancer Center in New York presented data from the Phase I study of allogeneic cryopreserved natural killer (NK) cell therapy candidate GDA-201 in patients with CD20 positive non-Hodgkin lymphoma. Learn more about the poster presentations in our press release: https://lnkd.in/euzmjQMm #celltherapy #ASTCT #CIBMTR

Learn more about OMISIRGE® (omidubicel-onlv) at ASTCT On February 21, 1:30-2:30pm CT Dr. Ronit Simantov, Gamida Cell Chief Medical & Scientific Officer will present “Latest Advancements in Allo-HCT” WARNING: INFUSION REACTIONS, GRAFT VERSUS HOST DISEASE, ENGRAFTMENT SYNDROME, and GRAFT FAILURE. See Full Prescribing Information, including Boxed Warning, at https://lnkd.in/etxVyNF2 or visit Omisirge.com

The Tandem Meetings are coming up on February 21-25! Visit Gamida Cell at Booth #604 to learn more about OMISIRGE® (omidubicel-onlv). See full Prescribing Information, including Boxed Warning, here: https://lnkd.in/etxVyNF2

Today is #NationalDonorDay , a day to focus on the life-saving benefits of organ, tissue, marrow, platelet and blood donations. We also honor those who have given the gift of donation and recognize those who have received a donation. According to NMDP , 70% of patients who need an allogeneic stem cell transplant do not have a fully matched stem cell transplant donor in their family and may depend on an unrelated donor to save their life. Learn more about the life-saving potential of the donor registry at https://lnkd.in/edZgRd2f #NMDP Note: Gamida Cell is not responsible for and does not endorse the content found within third party websites.

Metric
Company Name	Gamida Cell	Dexcel Pharma
Symbol
MSH ID	COM:GAMIDA-CELL	COM:DEXCEL
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals
Country	IL	IL
Stage
Employee Count
Website	gamida-cell.com	dexcel.com
LinkedIn	gamida-cell-ltd-	dexcel-pharma
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:GAMIDA-CELL

Gamida Cell

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue